AA
AMAG

AlphaMark Advisors’s AMAG Pharmaceuticals AMAG Stock Holding History

AlphaMark Advisors’s Portfolio AMAG Stock Details AMAG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-27,953
Closed -$559K – 525
2018
Q3 		$559K Buy
+27,953
New +$636K 0.23% 87

Other funds holding AMAG

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $70.2B AUM 29.99% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

AlphaMark Advisors's AMAG Position: Q4 2018 in Review

AlphaMark Advisors sold out of AMAG Pharmaceuticals (AMAG) in Q4 2018, closing a stake of 27,953 shares — an estimated $559K sold.

AlphaMark Advisors first reported a position in AMAG in Q3 2018 and held it in 1 quarter. The position peaked at $559K in Q3 2018. 190 funds tracked by Wall St. Rank hold AMAG as of Q4 2018.

  • AlphaMark Advisors reported no remaining AMAG Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • AlphaMark Advisors sold 27,953 AMAG Pharmaceuticals shares in Q4 2018, an estimated $559K.
  • AlphaMark Advisors first reported a position in AMAG Pharmaceuticals in Q3 2018 and held it in 1 quarter.
  • AlphaMark Advisors's AMAG Pharmaceuticals position peaked at $559K in Q3 2018.
  • 190 funds tracked by Wall St. Rank held AMAG Pharmaceuticals as of Q4 2018.

Based on AlphaMark Advisors's 13F filing for Q4 2018, filed 6 Feb 2019.